Pyrrolidine dithiocarbamate down-regulates vascular matrix metalloproteinases and ameliorates vascular dysfunction and remodelling in renovascular hypertension

British Journal of Pharmacology

Volumn 164, Issue 2, 2011, Pages 372-381

  Cau, S B A ^a   Guimaraes, D A ^a   Rizzi, E ^a   Ceron, C S ^a   Souza, L L ^a   Tirapelli, C R ^b   Gerlach, R F ^a   Tanus Santos, J E ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Department of Psychiatric Nursing and Human Sciences   (Brazil)

Author keywords

2K1C hypertension; matrix metalloproteinase; NF B; pyrrolidine dithiocarbamate; vascular remodelling

Indexed keywords

GELATINASE A; GELATINASE B; INDUCIBLE NITRIC OXIDE SYNTHASE; PYRROLIDINE DITHIOCARBAMATE; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR RELA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA WALL; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIAL DYSFUNCTION; ENZYME INDUCTION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; HISTOPATHOLOGY; IMMUNOFLUORESCENCE TEST; MALE; MORPHOMETRICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RENOVASCULAR HYPERTENSION; SHAM PROCEDURE; SYSTOLIC BLOOD PRESSURE; TISSUE LEVEL; TREATMENT DURATION; VASCULAR ENDOTHELIUM; VASCULAR RING; VASODILATATION; ZYMOGRAPHY;

ANIMALS; ANTIHYPERTENSIVE AGENTS; AORTA; GENE EXPRESSION REGULATION; HYPERTENSION, RENAL; HYPERTROPHY; MALE; METALLOPROTEASES; NF-KAPPA B; NITRIC OXIDE SYNTHASE TYPE II; PYRROLIDINES; RATS; RATS, WISTAR; THIOCARBAMATES;

EID: 80051956734     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01360.x     Document Type: Article

References (36)

1. Beswick RA, Zhang H, Marable D, Catravas JD, Hill WD, Webb RC, (2001). Long-term antioxidant administration attenuates mineralocorticoid hypertension and renal inflammatory response. Hypertension 37: 781-786. (Pubitemid 32199066)
2. Birukov KG, (2009). Cyclic stretch, reactive oxygen species, and vascular remodeling. Antioxid Redox Signal 11: 1651-1667.
3. Brasier AR, Recinos A, 3rd, Eledrisi MS, (2002). Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol 22: 1257-1266. (Pubitemid 34875734)
4. Browatzki M, Larsen D, Pfeiffer CA, Gehrke SG, Schmidt J, Kranzhofer A, et al,. (2005). Angiotensin II stimulates matrix metalloproteinase secretion in human vascular smooth muscle cells via nuclear factor-kappaB and activator protein 1 in a redox-sensitive manner. J Vasc Res 42: 415-423. (Pubitemid 41368960)
5. Castier Y, Ramkhelawon B, Riou S, Tedgui A, Lehoux S, (2009). Role of NF-kappaB in flow-induced vascular remodeling. Antioxid Redox Signal 11: 1641-1649.
6. Castro MM, Rizzi E, Figueiredo-Lopes L, Fernandes K, Bendhack LM, Pitol DL, et al,. (2008). Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats. Atherosclerosis 198: 320-331. (Pubitemid 351707391)
7. Castro MM, Rizzi E, Rodrigues GJ, Ceron CS, Bendhack LM, Gerlach RF, et al,. (2009). Antioxidant treatment reduces matrix metalloproteinase-2-induced vascular changes in renovascular hypertension. Free Radic Biol Med 46: 1298-1307.
8. Castro MM, Rizzi E, Prado CM, Rossi MA, Tanus-Santos JE, Gerlach RF, (2010). Imbalance between matrix metalloproteinases and tissue inhibitor of metalloproteinases in hypertensive vascular remodeling. Matrix Biol 29: 194-201.
9. Cauwe B, Van den Steen PE, Opdenakker G, (2007). The biochemical, biological, and pathological kaleidoscope of cell surface substrates processed by matrix metalloproteinases. Crit Rev Biochem Mol Biol 42: 113-185. (Pubitemid 46911962)
10. Ceron CS, Castro MM, Rizzi E, Montenegro MF, Fontana V, Salgado MC, et al,. (2010). Spironolactone and hydrochlorothiazide exert antioxidant effects and reduce vascular matrix metalloproteinase-2 activity and expression in a model of renovascular hypertension. Br J Pharmacol 160: 77-87.
11. Chow AK, Cena J, Schulz R, (2007). Acute actions and novel targets of matrix metalloproteinases in the heart and vasculature. Br J Pharmacol 152: 189-205. (Pubitemid 47517601)
12. Clark IM, Swingler TE, Sampieri CL, Edwards DR, (2008). The regulation of matrix metalloproteinases and their inhibitors. Int J Biochem Cell Biol 40: 1362-1378.
13. Dao HH, Lemay J, de Champlain J, deBlois D, Moreau P, (2001). Norepinephrine-induced aortic hyperplasia and extracellular matrix deposition are endothelin-dependent. J Hypertens 19: 1965-1973. (Pubitemid 33035801)
14. Flamant M, Placier S, Dubroca C, Esposito B, Lopes I, Chatziantoniou C, et al,. (2007). Role of matrix metalloproteinases in early hypertensive vascular remodeling. Hypertension 50: 212-218. (Pubitemid 46986043)
15. Guo RW, Yang LX, Wang H, Liu B, Wang L, (2008). Angiotensin II induces matrix metalloproteinase-9 expression via a nuclear factor-kappaB-dependent pathway in vascular smooth muscle cells. Regul Pept 147: 37-44.
16. Henke N, Schmidt-Ullrich R, Dechend R, Park JK, Qadri F, Wellner M, et al,. (2007). Vascular endothelial cell-specific NF-kappaB suppression attenuates hypertension-induced renal damage. Circ Res 101: 268-276. (Pubitemid 47344076)
17. Hong HJ, Loh SH, Yen MH, (2000). Suppression of the development of hypertension by the inhibitor of inducible nitric oxide synthase. Br J Pharmacol 131: 631-637.
18. Humphrey JD, (2008). Mechanisms of arterial remodeling in hypertension: coupled roles of wall shear and intramural stress. Hypertension 52: 195-200.
19. Intengan HD, Schiffrin EL, (2001). Vascular remodeling in hypertension: roles of apoptosis, inflammation, and fibrosis. Hypertension 38: 581-587.
20. Kandasamy AD, Chow AK, Ali MA, Schulz R, (2010). Matrix metalloproteinase-2 and myocardial oxidative stress injury: beyond the matrix. Cardiovasc Res 85: 413-423.
21. Lemarie CA, Tharaux PL, Esposito B, Tedgui A, Lehoux S, (2006). Transforming growth factor-alpha mediates nuclear factor kappaB activation in strained arteries. Circ Res 99: 434-441. (Pubitemid 44253700)
22. Lemarie CA, Tharaux PL, Lehoux S, (2010). Extracellular matrix alterations in hypertensive vascular remodeling. J Mol Cell Cardiol 48: 433-439.
23. Martinez ML, Castro MM, Rizzi E, Fernandes K, Demacq C, Bendhack LM, et al,. (2008). Lercanidipine reduces matrix metalloproteinase-2 activity and reverses vascular dysfunction in renovascular hypertensive rats. Eur J Pharmacol 591: 224-230.
24. Martinez-Maldonado M, (1991). Pathophysiology of renovascular hypertension. Hypertension 17: 707-719.
25. Muller DN, Dechend R, Mervaala EM, Park JK, Schmidt F, Fiebeler A, et al,. (2000). NF-kappaB inhibition ameliorates angiotensin II-induced inflammatory damage in rats. Hypertension 35 (1 Pt 2): 193-201. (Pubitemid 30054172)
26. Murphy G, Nagase H, (2008). Progress in matrix metalloproteinase research. Mol Aspects Med 29: 290-308.
27. Newby AC, (2006). Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates. Cardiovasc Res 69: 614-624. (Pubitemid 43140745)
28. Pacher P, Schulz R, Liaudet L, Szabo C, (2005). Nitrosative stress and pharmacological modulation of heart failure. Trends Pharmacol Sci 26: 302-310. (Pubitemid 40733523)
29. Rodriguez-Iturbe B, Ferrebuz A, Vanegas V, Quiroz Y, Mezzano S, Vaziri ND, (2005). Early and sustained inhibition of nuclear factor-kappaB prevents hypertension in spontaneously hypertensive rats. J Pharmacol Exp Ther 315: 51-57. (Pubitemid 41380497)
30. Schreck R, Meier B, Mannel DN, Droge W, Baeuerle PA, (1992). Dithiocarbamates as potent inhibitors of nuclear factor kappa B activation in intact cells. J Exp Med 175: 1181-1194.
31. Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT, (2002). Aldosterone-induced inflammation in the rat heart: role of oxidative stress. Am J Pathol 161: 1773-1781. (Pubitemid 35265535)
32. Van der Heiden K, Cuhlmann S, Luong A, Zakkar M, Evans PC, (2010). Role of nuclear factor kappaB in cardiovascular health and disease. Clin Sci (Lond) 118: 593-605.
33. Watts SW, Rondelli C, Thakali K, Li X, Uhal B, Pervaiz MH, et al,. (2007). Morphological and biochemical characterization of remodeling in aorta and vena cava of DOCA-salt hypertensive rats. Am J Physiol Heart Circ Physiol 292: H2438-H2448. (Pubitemid 47084627)
34. Zahradka P, Werner JP, Buhay S, Litchie B, Helwer G, Thomas S, (2002). NF-kappaB activation is essential for angiotensin II-dependent proliferation and migration of vascular smooth muscle cells. J Mol Cell Cardiol 34: 1609-1621. (Pubitemid 35454476)
35. Zhang L, Cheng J, Ma Y, Thomas W, Zhang J, Du J, (2005). Dual pathways for nuclear factor kappaB activation by angiotensin II in vascular smooth muscle: phosphorylation of p65 by IkappaB kinase and ribosomal kinase. Circ Res 97: 975-982. (Pubitemid 41668910)
36. Zhou MS, Schulman IH, Raij L, (2010). Vascular inflammation, insulin resistance, and endothelial dysfunction in salt-sensitive hypertension: role of nuclear factor kappa B activation. J Hypertens 28: 527-535.